Clinical Trial Update: Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. [Phase 3]

View source ↗

Summary

Phase III clinical trial evaluating recombinant human TNK-tPA (rhTNK-tPA) for acute ischemic stroke with an extended time window is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• rhTNK-tPA (tenecteplase)

Snippet

Sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | Conditions: Acute Ischemic Stroke | Phase 3 | Status: RECRUITING